Parecoxib for Treatment of Catheter Related Bladder Discomfort

Participants will be randomized into one of two study groups: Group P: 40 mg of intravenous parecoxib 30 min before surgery and Control Group C: an equal volume of saline.

Lumber subarachnoid block was administered with 2 ml 0.5% hyperbaric bupivacaine and 2.5 µg Sufentanyl. Intra-operatively, urinary catherization was performed with a 16 Fr Foley's catheter, and the balloon was inflated with 10 ml distilled water. The CRBD was assessed at 0, 1, 2, and 6 h after patient's arrival in the post-anaesthesia care unit. Severity of CRBD was graded as none, mild, moderate and severe.

Inclusion criteria

• Adult (>/=18)
• Male or female
• Undergoing catheterization after transurethral resection of bladder tumor (TURBT)
• Under spinal anesthesia
• Subject is American Society of Anesthesiologists (ASA) physical status 1 or 2.

Exclusion criteria

• Patient who disagrees to participate this investigation
• Patient with severe cardiovascular disease
• Patient with small-sized foley catheter (less than 18 Fr.)
• Patinets with bladder outflow obstruction
• Patient with overactive bladder (frequency >3 times,in the night or >8 times in 24 h)
• Patients with chronic renal failure
• Patient with morbid obesity
• Patient with medications for chronic pain
• Patient with disturbance of the central nervous system